All News Gan & Lee Pharmaceuticals.

Equities

603087

CNE100003ZH1

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
48.52 ^CNY	+0.06%		+4.46%	-7.84%

May. 24	Gan & Lee Pharmaceuticals Gets Mexico's Drug Registration Approval for Insulin Glargine Injection	MT
Apr. 24	Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gan & Lee Pharmaceuticals Gets Mexico's Drug Registration Approval for Insulin Glargine Injection	May. 24	MT
Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
Gan & Lee Pharma's Insulin Product Gets Registration Approval in Bolivia	Jan. 26	MT
Gan & Lee Pharmaceuticals Administers First Subject in Phase II Study of GZR101 Diabetes Drug	Dec. 12	MT
Gan & Lee Pharmaceuticals' Unit Gets Nod to Test GZR18 Tablets	Dec. 04	MT
Gan & Lee Pharmaceuticals. announced that it has received CNY 773.151876 million in funding	Nov. 09	CI
Type 1 Diabetes Pipeline\| Clinical Trials and Key Companies - Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma	Nov. 09	AQ
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Gan & Lee Pharma’s Insulin Analogs Gain EU Regulatory Approval	23-10-12	MT
Gan & Lee Pharmaceuticals.(XSSC:603087) added to S&P Global BMI Index	23-09-18	CI
Gan & Lee Pharmaceuticals.(XSSC:603087) added to FTSE All-World Index	23-09-18	CI
Gan & Lee Pharma Advances Trial of New Insulin Product	23-09-13	MT
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-18	CI
Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1023 Injection	23-07-20	MT
Gan & Lee Pharmaceuticals Gets Regulatory Nod for Private Placement	23-06-20	MT
Pharmaktiv acquired remaining 51% stake in Endogenix LLC from Gan & Lee Pharmaceuticals..	23-06-13	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
FDA Accepts Gan & Lee Pharma's Application for Insulin Glargine Injection	23-02-24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Gan & Lee Pharmaceuticals.

Equities

603087

CNE100003ZH1

All News

Filters